Sector News

Europe’s pharma chiefs seek stronger China ties

September 29, 2014
Life sciences
Heavyweights from the European pharmaceutical industry have concluded a successful trip to China, aimed at strengthening ties with the sector and government in the country.
 
A high-level delegation from the European Federation of Pharmaceutical Industries and Associations have just returned from Beijing, including president and Sanofi chief executive Chris Viehbacher, EFPIA director-general Richard Bergstrom and the heads of UCB and Merck Serono, Roch Doliveux and Stefan Oschmann. They took part in a public conference on ‘translational medicine in a global world and a workshop on transparency and good governance, as well as an industry regulatory symposium.
 
Mr Viehbacher noted that China’s growing life sciences sector “is paving the way for the country to become an increasingly influential player in drug development”, adding that the visit “marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place” in China.
 
Dr Oschmann stated that China’s “commitments to reform healthcare and further develop a stronger biopharmaceutical sector go hand in hand”. He claimed that “to improve patient access to high-quality healthcare and to become a truly global innovator, China should continue to work towards creating an environment that supports innovation”.  
 
EFPIA notes that China’s pharmaceutical output has increased by 719% since 2000 and venture capital investments in the sector have grown from $7 million to $491 million over the same period. A growing number of global drugmakers have set up R&D centres in China over the last few years, including AstraZeneca and Novo Nordisk in 2002, Eli Lilly and GlaxoSmithKline in 2003 and Roche in 2004; since then, Pfizer, Sanofi and Johnson & Johnson have also established research bases there, among others.
 
The visit came days after GSK was ordered to pay £297 million to the Chinese government after having been found guilty of bribing doctors to prescribe its medicines.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach